Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)
Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –
Protagonist Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Protagonist Therapeutics's pe ratio was 130.9× on Nov 11, 2026, against 63.3× a year earlier. Over the last 2 years it ranged from 8.9× to 145.2×, with a median of 63.3×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 130.9× | −9.9 |
| 2025 | Dec 31, 2025 | 140.9× | +126.4 |
| 2024 | Dec 31, 2024 | 14.5× | – |
See a number that looks wrong?